1
|
Drebrin promotes lung adenocarcinoma cell migration through inducing integrin β1 endocytosis. Biochem Biophys Res Commun 2022; 630:175-182. [PMID: 36155064 DOI: 10.1016/j.bbrc.2022.09.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2022] [Revised: 09/01/2022] [Accepted: 09/12/2022] [Indexed: 11/22/2022]
Abstract
Lung adenocarcinoma (LUAD) is the most common type of lung cancers, which remains the leading cause of cancer-related death worldwide. Drebrin can promote cell migration and invasion with poor prognosis, but its roes in LUAD tumor progression remains unknown. We showed that the expression of Drebrin was upregulated in clinical LUAD samples. A Kaplan-Meier survival analysis showed that a high expression of Drebrin predicated poor prognosis in LUAD. In vitro, Drebrin promoted anchorage-independent growth and migration of LUAD cells. Drebrin interacted with dynamin through CT domain, and served as an adaptor to promote LUAD cell migration through inducing integrin β1 endocytosis. Thus, this study demonstrated the critical role of Drebrin in LUAD and associated mechanism.
Collapse
|
2
|
Alfarsi LH, El Ansari R, Masisi BK, Parks R, Mohammed OJ, Ellis IO, Rakha EA, Green AR. Integrated Analysis of Key Differentially Expressed Genes Identifies DBN1 as a Predictive Marker of Response to Endocrine Therapy in Luminal Breast Cancer. Cancers (Basel) 2020; 12:cancers12061549. [PMID: 32545448 PMCID: PMC7352383 DOI: 10.3390/cancers12061549] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2020] [Revised: 06/08/2020] [Accepted: 06/10/2020] [Indexed: 12/26/2022] Open
Abstract
Endocrine therapy is the mainstay of adjuvant treatment for patients with luminal breast cancer. Despite ongoing advances in endocrine therapy to date, a proportion of patients ultimately develop endocrine resistance, resulting in failure of therapy and poor prognosis. Therefore, as part of the growing concept of personalised medicine, the need for identification of predictive markers of endocrine therapy response at an early stage, is recognised. The METABRIC series was used to identify differentially expressed genes (DEGs) in term of response to adjuvant endocrine therapy. Drebrin 1 (DBN1) was identified as a key DEG associated with response to hormone treatment. Next, large, well-characterised cohorts of primary luminal breast cancer with long-term follow-up were assessed at the mRNA and protein levels for the value of DBN1 as a prognostic marker in luminal breast cancer, as well as its potential for predicting the benefit of endocrine therapy. DBN1 positivity was associated with aggressive clinicopathological variables and poor patient outcomes. Importantly, high DBN1 expression predicted relapse patients who were subject to adjuvant endocrine treatment. Our results further demonstrate that DBN1 is an independent prognostic marker in luminal breast cancer. Its association with the response to endocrine therapy and outcome provides evidence for DBN1 as a potential biomarker in luminal breast cancer, particularly for the benefit of endocrine treatment. Further functional investigations into the mechanisms underlying sensitivity to endocrine therapy is required.
Collapse
Affiliation(s)
- Lutfi H. Alfarsi
- Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK; (L.H.A.); (R.E.A.); (B.K.M.); (R.P.); (O.J.M.); (I.O.E.); (E.A.R.)
| | - Rokaya El Ansari
- Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK; (L.H.A.); (R.E.A.); (B.K.M.); (R.P.); (O.J.M.); (I.O.E.); (E.A.R.)
| | - Brendah K. Masisi
- Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK; (L.H.A.); (R.E.A.); (B.K.M.); (R.P.); (O.J.M.); (I.O.E.); (E.A.R.)
| | - Ruth Parks
- Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK; (L.H.A.); (R.E.A.); (B.K.M.); (R.P.); (O.J.M.); (I.O.E.); (E.A.R.)
| | - Omar J Mohammed
- Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK; (L.H.A.); (R.E.A.); (B.K.M.); (R.P.); (O.J.M.); (I.O.E.); (E.A.R.)
| | - Ian O. Ellis
- Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK; (L.H.A.); (R.E.A.); (B.K.M.); (R.P.); (O.J.M.); (I.O.E.); (E.A.R.)
- Cellular Pathology, Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK
| | - Emad A. Rakha
- Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK; (L.H.A.); (R.E.A.); (B.K.M.); (R.P.); (O.J.M.); (I.O.E.); (E.A.R.)
- Cellular Pathology, Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Hucknall Road, Nottingham NG5 1PB, UK
| | - Andrew R. Green
- Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham Biodiscovery Institute, University Park, Nottingham NG7 2RD, UK; (L.H.A.); (R.E.A.); (B.K.M.); (R.P.); (O.J.M.); (I.O.E.); (E.A.R.)
- Correspondence: ; Tel.: +44-115-8231407
| |
Collapse
|
3
|
Yin Y, Li B, Mou K, Khan MT, Kaushik AC, Wei D, Zhang YJ. Stoichioproteomics reveal oxygen usage bias, key proteins and pathways in glioma. BMC Med Genomics 2019; 12:125. [PMID: 31464612 PMCID: PMC6716898 DOI: 10.1186/s12920-019-0571-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2019] [Accepted: 08/12/2019] [Indexed: 02/08/2023] Open
Abstract
Background The five-year survival rate and therapeutic effect of malignant glioma is low. Identification of key/associated proteins and pathways in glioma is necessary for developing effective diagnosis and targeted therapy of glioma. In addition, Glioma involves hypoxia-specific microenvironment, whether hypoxia restriction influences the stoichioproteomic characteristics of expressed proteins is unknown. Methods In this study, we analyzed the most comprehensive immunohistochemical data from 12 human glioma samples and 4 normal cell types of cerebral cortex, identified differentially expressed proteins (DEPs), and researched the oxygen contents of DEPs, highly and lowly expressed proteins. Further we located key genes on human genome to determine their locations and enriched them for key functional pathways. Results Our results showed that although no difference was detected on whole proteome, the average oxygen content of highly expressed proteins is 6.65% higher than that of lowly expressed proteins in glioma. A total of 1480 differentially expressed proteins were identified in glioma, including 226 up regulated proteins and 1254 down regulated proteins. The average oxygen content of up regulated proteins is 2.56% higher than that of down regulated proteins in glioma. The localization of differentially expressed genes on human genome showed that most genes were on chromosome 1 and least on Y. The up regulated proteins were significantly enriched in pathways including cell cycle, pathways in cancer, oocyte meiosis, DNA replication etc. Functional dissection of the up regulated proteins with high oxygen contents showed that 51.28% of the proteins were involved in cell cycle and cyclins. Conclusions Element signature of oxygen limitation could not be detected in glioma, just as what happened in plants and microbes. Unsaved use of oxygen by the highly expressed proteins and DEPs were adapted to the fast division of glioma cells. This study can help to reveal the molecular mechanism of glioma, and provide a new approach for studies of cancer-related biomacromolecules. In addition, this study lays a foundation for application of stoichioproteomics in precision medicine. Electronic supplementary material The online version of this article (10.1186/s12920-019-0571-y) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Yongqin Yin
- Chongqing Key Laboratory of Vector Insects, Institute of Entomology and Molecular Biology, College of Life Sciences, Chongqing Normal University, Shapingba, University City, Chongqing, 401331, People's Republic of China
| | - Bo Li
- Chongqing Key Laboratory of Vector Insects, Institute of Entomology and Molecular Biology, College of Life Sciences, Chongqing Normal University, Shapingba, University City, Chongqing, 401331, People's Republic of China
| | - Kejie Mou
- Department of Neurosurgery, Bishan Hospital, Bishan, Chongqing, 402760, China
| | - Muhammad T Khan
- Shanghai Jiao Tong University, Shanghai, China.,Capital University of Science & Technology, Islamabad, Pakistan
| | | | - Dongqing Wei
- Shanghai Jiao Tong University, Shanghai, China. .,Peng Cheng Laboratory, Vanke Cloud City Phase I Building 8, Xili Street, Nanshan District, Shenzhen, Guangdong, 518055, China.
| | - Yu-Juan Zhang
- Chongqing Key Laboratory of Vector Insects, Institute of Entomology and Molecular Biology, College of Life Sciences, Chongqing Normal University, Shapingba, University City, Chongqing, 401331, People's Republic of China.
| |
Collapse
|
4
|
Yin W, Tang G, Zhou Q, Cao Y, Li H, Fu X, Wu Z, Jiang X. Expression Profile Analysis Identifies a Novel Five-Gene Signature to Improve Prognosis Prediction of Glioblastoma. Front Genet 2019; 10:419. [PMID: 31130992 PMCID: PMC6509566 DOI: 10.3389/fgene.2019.00419] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2018] [Accepted: 04/17/2019] [Indexed: 12/12/2022] Open
Abstract
Glioblastoma multiforme (GBM) is the most aggressive primary central nervous system malignant tumor. The median survival of GBM patients is 12–15 months, and the 5 years survival rate is less than 5%. More novel molecular biomarkers are still urgently required to elucidate the mechanisms or improve the prognosis of GBM. This study aimed to explore novel biomarkers for GBM prognosis prediction. The gene expression profiles from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets of GBM were downloaded. A total of 2241 overlapping differentially expressed genes (DEGs) were identified from TCGA and GSE7696 datasets. By univariate COX regression survival analysis, 292 survival-related genes were found among these DEGs (p < 0.05). Functional enrichment analysis was performed based on these survival-related genes. A five-gene signature (PTPRN, RGS14, G6PC3, IGFBP2, and TIMP4) was further selected by multivariable Cox regression analysis and a prognostic model of this five-gene signature was constructed. Based on this risk score system, patients in the high-risk group had significantly poorer survival results than those in the low-risk group. Moreover, with the assistance of GEPIA http://gepia.cancer-pku.cn/, all five genes were found to be differentially expressed in GBM tissues compared with normal brain tissues. Furthermore, the co-expression network of the five genes was constructed based on weighted gene co-expression network analysis (WGCNA). Finally, this five-gene signature was further validated in other datasets. In conclusion, our study identified five novel biomarkers that have potential in the prognosis prediction of GBM.
Collapse
Affiliation(s)
- Wen Yin
- Department of Neurosurgery, Xiangya Hospital of Central South University, Changsha, China
| | - Guihua Tang
- Department of Clinical Laboratory, Hunan Provincial People's Hospital (First Affiliated Hospital of Hunan Normal University), Changsha, China
| | - Quanwei Zhou
- Department of Neurosurgery, Xiangya Hospital of Central South University, Changsha, China
| | - Yudong Cao
- Department of Neurosurgery, Xiangya Hospital of Central South University, Changsha, China
| | - Haixia Li
- Department of Operative Nursing, Xiangya Hospital of Central South University, Changsha, China
| | - Xianyong Fu
- Department of Neurosurgery, Xiangya Hospital of Central South University, Changsha, China
| | - Zhaoping Wu
- Department of Neurosurgery, Xiangya Hospital of Central South University, Changsha, China
| | - Xingjun Jiang
- Department of Neurosurgery, Xiangya Hospital of Central South University, Changsha, China
| |
Collapse
|
5
|
Xu A, Chen J, Peng H, Han G, Cai H. Simultaneous Interrogation of Cancer Omics to Identify Subtypes With Significant Clinical Differences. Front Genet 2019; 10:236. [PMID: 30984238 PMCID: PMC6448130 DOI: 10.3389/fgene.2019.00236] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2018] [Accepted: 03/04/2019] [Indexed: 11/21/2022] Open
Abstract
Recent advances in high-throughput sequencing have accelerated the accumulation of omics data on the same tumor tissue from multiple sources. Intensive study of multi-omics integration on tumor samples can stimulate progress in precision medicine and is promising in detecting potential biomarkers. However, current methods are restricted owing to highly unbalanced dimensions of omics data or difficulty in assigning weights between different data sources. Therefore, the appropriate approximation and constraints of integrated targets remain a major challenge. In this paper, we proposed an omics data integration method, named high-order path elucidated similarity (HOPES). HOPES fuses the similarities derived from various omics data sources to solve the dimensional discrepancy, and progressively elucidate the similarities from each type of omics data into an integrated similarity with various high-order connected paths. Through a series of incremental constraints for commonality, HOPES can take both specificity of single data and consistency between different data types into consideration. The fused similarity matrix gives global insight into patients' correlation and efficiently distinguishes subgroups. We tested the performance of HOPES on both a simulated dataset and several empirical tumor datasets. The test datasets contain three omics types including gene expression, DNA methylation, and microRNA data for five different TCGA cancer projects. Our method was shown to achieve superior accuracy and high robustness compared with several benchmark methods on simulated data. Further experiments on five cancer datasets demonstrated that HOPES achieved superior performances in cancer classification. The stratified subgroups were shown to have statistically significant differences in survival. We further located and identified the key genes, methylation sites, and microRNAs within each subgroup. They were shown to achieve high potential prognostic value and were enriched in many cancer-related biological processes or pathways.
Collapse
Affiliation(s)
- Aodan Xu
- School of Computer Science and Engineering, South China University of Technology, Guangzhou, China
| | - Jiazhou Chen
- School of Computer Science and Engineering, South China University of Technology, Guangzhou, China
| | - Hong Peng
- School of Computer Science and Engineering, South China University of Technology, Guangzhou, China
| | - GuoQiang Han
- School of Computer Science and Engineering, South China University of Technology, Guangzhou, China
| | - Hongmin Cai
- School of Computer Science and Engineering, South China University of Technology, Guangzhou, China
| |
Collapse
|
6
|
Cytometric analysis of cell suspension generated by cavitron ultrasonic surgical aspirator in pediatric brain tumors. J Neurooncol 2019; 143:15-25. [PMID: 30827009 DOI: 10.1007/s11060-019-03135-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2019] [Accepted: 02/23/2019] [Indexed: 12/15/2022]
Abstract
PURPOSE The aim of this study was to test the possibility of using specimens obtained by a cavitron ultrasonic surgical aspirator (CUSA) in flow and mass cytometry investigations of pediatric brain tumors. METHODS CUSA specimens obtained from 19 pediatric patients with brain tumors were investigated. Flow and mass cytometry methods were applied to analyze the composition of material collected using the CUSA. Cell suspensions were prepared from CUSA aspirates. Then sample viability was assessed by conventional flow cytometry and subsequently stained with a panel of 31 metal-labeled antibodies. RESULTS Viability assessment was performed using conventional flow cytometry. Viability of cells in the acquired samples was below 50% in 16 of 19 cases. A mass cytometry investigation and subsequent analysis enabled us to discriminate brain tumor cells from contaminating leukocytes, whose proportions varied across the specimens. The addition of the viability marker cisplatin directly into the mass cytometry panel gave the means to selecting viable cells only for subsequent analyses. The proportion of non-viable cells was higher among tumor cells compared leukocytes. CONCLUSIONS When the analysis of the tumor cell immunophenotype is performed with markers for determining viability, the expression of the investigated markers can be evaluated. Suitable markers can be selected by high-throughput methods, such as mass cytometry, and those that are diagnostically relevant can be investigated using flow cytometry, which is more flexible in terms of time.
Collapse
|
7
|
Dang E, Yang S, Song C, Jiang D, Li Z, Fan W, Sun Y, Tao L, Wang J, Liu T, Zhang C, Jin B, Wang J, Yang K. BAP31, a newly defined cancer/testis antigen, regulates proliferation, migration, and invasion to promote cervical cancer progression. Cell Death Dis 2018; 9:791. [PMID: 30022068 PMCID: PMC6052025 DOI: 10.1038/s41419-018-0824-2] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2018] [Revised: 06/22/2018] [Accepted: 06/25/2018] [Indexed: 01/06/2023]
Abstract
Malignant tumors typically undergo an atavistic regression characterized by the overexpression of embryonic genes and proto-oncogenes, including a variety of cancer/testis antigens (CTAs) that are testis-derived and are not expressed or expressed in trace amounts in somatic tissues. Based on this theory, we established a new method to identify unknown CTAs, the spermatogenic cells-specific monoclonal antibody-defined cancer/testis antigen (SADA) method. Using the SADA method, we identified BAP31 as a novel CTA and confirmed that BAP31 expression is associated with progression and metastasis of several cancers, particularly in cervical cancer. We found that BAP31 was significantly upregulated in stage I, II, and III cervical cancer patients and highly correlated with poor clinic outcomes. We further demonstrated that BAP31 regulates cervical cancer cell proliferation by arresting the cell cycle at the G0/G1 stage and that depletion of BAP31 inhibits hyper-proliferation. Moreover, depletion of BAP31 inhibits cervical cancer cell invasion and migration by regulating the expression and subcellular localization of Drebrin, M-RIP, SPECC1L, and Nexilin, and then affect the cytoskeleton assemblage. Finally, the depletion of BAP31 prevents cervical cancer progression and metastasis in vivo. These findings provide a new method for identifying novel CTAs as well as mechanistic insights into how BAP31 regulates cervical cancer hyper-proliferation and metastasis.
Collapse
Affiliation(s)
- Erle Dang
- Department of Immunology, the Fourth Military Medical University, Xi'an, 710032, Shaanxi, People's Republic of China.,Department of Dermatology, Xijing Hospital, the Fourth Military Medical University, Xi'an, 710032, Shaanxi, People's Republic of China
| | - Shuya Yang
- Department of Immunology, the Fourth Military Medical University, Xi'an, 710032, Shaanxi, People's Republic of China
| | - Chaojun Song
- Department of Immunology, the Fourth Military Medical University, Xi'an, 710032, Shaanxi, People's Republic of China.,School of Life Science, Northwestern Polytechnic University, Xi'an, 710072, Shaanxi, People's Republic of China
| | - Dongbo Jiang
- Department of Immunology, the Fourth Military Medical University, Xi'an, 710032, Shaanxi, People's Republic of China
| | - Zichao Li
- Department of Immunology, the Fourth Military Medical University, Xi'an, 710032, Shaanxi, People's Republic of China
| | - Wei Fan
- Department of Obstetrics and Gynecology, Xijing Hospital, the Fourth Military Medical University, Xi'an, 710032, Shaanxi, People's Republic of China
| | - Yuanjie Sun
- Department of Immunology, the Fourth Military Medical University, Xi'an, 710032, Shaanxi, People's Republic of China
| | - Liang Tao
- Department of Immunology, the Fourth Military Medical University, Xi'an, 710032, Shaanxi, People's Republic of China
| | - Jing Wang
- Department of Immunology, the Fourth Military Medical University, Xi'an, 710032, Shaanxi, People's Republic of China
| | - Tingting Liu
- Department of Immunology, the Fourth Military Medical University, Xi'an, 710032, Shaanxi, People's Republic of China
| | - Chunmei Zhang
- Department of Immunology, the Fourth Military Medical University, Xi'an, 710032, Shaanxi, People's Republic of China
| | - Boquan Jin
- Department of Immunology, the Fourth Military Medical University, Xi'an, 710032, Shaanxi, People's Republic of China.
| | - Jian Wang
- Department of Obstetrics and Gynecology, Xijing Hospital, the Fourth Military Medical University, Xi'an, 710032, Shaanxi, People's Republic of China.
| | - Kun Yang
- Department of Immunology, the Fourth Military Medical University, Xi'an, 710032, Shaanxi, People's Republic of China.
| |
Collapse
|
8
|
Dart AE, Worth DC, Muir G, Chandra A, Morris JD, McKee C, Verrill C, Bryant RJ, Gordon-Weeks PR. The drebrin/EB3 pathway drives invasive activity in prostate cancer. Oncogene 2017; 36:4111-4123. [PMID: 28319065 PMCID: PMC5537610 DOI: 10.1038/onc.2017.45] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2016] [Revised: 01/13/2017] [Accepted: 02/02/2017] [Indexed: 02/06/2023]
Abstract
Prostate cancer is the most common cancer in men and the metastatic form of the disease is incurable. We show here that the drebrin/EB3 pathway, which co-ordinates dynamic microtubule/actin filament interactions underlying cell shape changes in response to guidance cues, plays a role in prostate cancer cell invasion. Drebrin expression is restricted to basal epithelial cells in benign human prostate but is upregulated in luminal epithelial cells in foci of prostatic malignancy. Drebrin is also upregulated in human prostate cancer cell lines and co-localizes with actin filaments and dynamic microtubules in filopodia of pseudopods of invading cells under a chemotactic gradient of the chemokine CXCL12. Disruption of the drebrin/EB3 pathway using BTP2, a small molecule inhibitor of drebrin binding to actin filaments, reduced the invasion of prostate cancer cell lines in 3D in vitro assays. Furthermore, gain- or loss-of-function of drebrin or EB3 by over-expression or siRNA-mediated knockdown increases or decreases invasion of prostate cancer cell lines in 3D in vitro assays, respectively. Finally, expression of a dominant-negative construct that competes with EB3 binding to drebrin, also inhibited invasion of prostate cancer cell lines in 3D in vitro assays. Our findings show that co-ordination of dynamic microtubules and actin filaments by the drebrin/EB3 pathway drives prostate cancer cell invasion and is therefore implicated in disease progression.
Collapse
Affiliation(s)
- A E Dart
- The MRC Centre for Developmental Neurobiology, King's College London, New Hunts House, Guy's Campus, London, UK
| | - D C Worth
- The MRC Centre for Developmental Neurobiology, King's College London, New Hunts House, Guy's Campus, London, UK
| | - G Muir
- Urology, King's College Hospital, London, UK
| | - A Chandra
- Cellular Pathology, 2nd floor North Wing, St. Thomas' Hospital, London, UK
| | - J D Morris
- Division of Cancer Studies, New Hunt's House, Guy's Campus, King's College London, London, UK
| | - C McKee
- Oxford Institute for Radiation Oncology, Churchill Hospital, University of Oxford, Oxford, UK
| | - C Verrill
- Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
| | - R J Bryant
- Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
| | - P R Gordon-Weeks
- The MRC Centre for Developmental Neurobiology, King's College London, New Hunts House, Guy's Campus, London, UK
| |
Collapse
|
9
|
Tsangaris GT, Papathanasiou C, Adamopoulos PG, Scorilas A, Vorgias CE, Prodromou N, Stathopoulou FT, Stravopodis DJ, Anagnostopoulos AK. Pediatric Ependymoma: A Proteomics Perspective. Cancer Genomics Proteomics 2017; 14:127-136. [PMID: 28387652 PMCID: PMC5369312 DOI: 10.21873/cgp.20025] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2017] [Revised: 02/25/2017] [Accepted: 02/28/2017] [Indexed: 01/14/2023] Open
Abstract
BACKGROUND/AIM Proteomics based on high-resolution mass spectrometry (MS) is the tool of choice for the analysis of protein presence, modifications and interactions, with increasing emphasis on the examination of tumor tissues. Application of MS-based proteomics offers a detailed picture of tumor tissue characteristics, facilitating the appreciation of different tumor entities, whilst providing reliable and fast results for therapeutic marker targeting and prognostic factor assessment. Through use of the high analytical resolution of nano-high-pressure liquid chromatography (nanoHPLC) and the high resolution of an Orbitrap Elite mass spectrometer, the present study aimed to provide knowledge on the proteome of the generally unknown entity of pediatric ependymal tumors. MATERIALS AND METHODS Ten resected specimens of childhood ependymoma were analyzed through a one-dimensional (1D) nanoLC-MS/MS approach. Method optimization steps were undertaken for both the sample preparation/protein extraction procedure and LC parameters, aiming to achieve the highest possible identification rates. RESULTS Following method optimization, each nanoLC-MS/MS run resulted in identification of more than 5,000 proteins and more than 25,000 peptides for every analyzed sample, thus detailing the greater part of the ependymoma proteome. Identified proteins were found to spread throughout all known tumor categories regarding their molecular function and subcellular localization. CONCLUSION Through the proposed nanoLC-MS/MS method herein we report, for the firs time, the ependymoma proteome database. A large number of similarities regarding proteome content are revealed compared to other two pediatric brain tumor entities; astrocytomas and medulloblastomas. Furthermore, through our approach, the majority of currently proposed markers for ependymoma (e.g. nucleolin, nestin, Ki67 and laminin subunit A2) as well as all major key players of the phosphoinositide 3-kinase pathway (seemingly implicated in ependymoma), were definitely detected.
Collapse
Affiliation(s)
- George Th Tsangaris
- Proteomics Research Unit, Biomedical Research Foundation of the Academy of Athens, Athens, Greece
| | - Chrissa Papathanasiou
- Hematology/Oncology Unit, First Department of Pediatrics, University of Athens, Aghia Sophia Children's Hospital, Athens, Greece
| | | | - Andreas Scorilas
- Department of Biochemistry and Molecular Biology, Faculty of Biology, School of Sciences, National and Kapodistrian University of Athens, Athens, Greece
| | - Constantinos E Vorgias
- Department of Biochemistry and Molecular Biology, Faculty of Biology, School of Sciences, National and Kapodistrian University of Athens, Athens, Greece
| | - Neofytos Prodromou
- Department of Neurosurgery, Aghia Sophia Children's Hospital, Athens, Greece
| | - Foteini Tzortzatou Stathopoulou
- Hematology/Oncology Unit, First Department of Pediatrics, University of Athens, Aghia Sophia Children's Hospital, Athens, Greece
| | - Dimitrios J Stravopodis
- Department of Cell Biology and Biophysics, Faculty of Biology, School of Sciences, National and Kapodistrian University of Athens, Athens, Greece
| | | |
Collapse
|
10
|
Homer, Spikar, and Other Drebrin-Binding Proteins in the Brain. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2017; 1006:249-268. [PMID: 28865024 DOI: 10.1007/978-4-431-56550-5_14] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Drebrin is a major F-actin-binding protein in the brain. In the past two decades, many drebrin-binding proteins in addition to F-actin have been identified in several research fields including neuroscience, oncology, and immunology. Among the drebrin-binding proteins, there are various kinds of proteins including scaffold proteins, nuclear proteins, phosphatases, microtubule-binding proteins, G-actin-binding proteins, gap junction proteins, chemokine receptors, and cell-adhesion-related proteins. The interaction between drebrin and its binding partners seems to play important roles in higher brain functions, because drebrin is involved in the pathogenesis of some neurological diseases with cognitive defects. In this chapter, we will first review the interaction of Homer and spikar with drebrin, particularly focusing on spine morphogenesis and synaptic function. Homer contributes to spine morphogenesis by cooperating with shank and activated Cdc42 small GTPase, suggesting a novel signaling pathway comprising Homer, drebrin, shank, and Cdc42 for spine morphogenesis. Drebrin sequesters spikar in the cytoplasm and stabilizes it in dendritic spines, leading to spine formation. Finally, we will introduce some other drebrin-binding proteins including end-binding protein 3 (EB3), profilin, progranulin, and phosphatase and tensin homologue (PTEN). These proteins are involved in Alzheimer's disease and cancer. Therefore, further studies on drebrin and its binding proteins will be of great importance to elucidate the pathologies of various diseases and may contribute to their medical treatment and diagnostics development.
Collapse
|
11
|
The Role of Drebrin in Cancer Cell Invasion. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2017; 1006:375-389. [DOI: 10.1007/978-4-431-56550-5_23] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
12
|
|
13
|
Abstract
Drebrin is a family of actin-binding proteins with two known members called drebrin A and E. Apart from the ability to stabilize F-actin microfilaments via their actin-binding domains near the N-terminus, drebrin also regulates multiple cellular functions due to its unique ability to recruit multiple binding partners to a specific cellular domain, such as the seminiferous epithelium during the epithelial cycle of spermatogenesis. Recent studies have illustrated the role of drebrin E in the testis during spermatogenesis in particular via its ability to recruit branched actin polymerization protein known as actin-related protein 3 (Arp3), illustrating its involvement in modifying the organization of actin microfilaments at the ectoplasmic specialization (ES) which includes the testis-specific anchoring junction at the Sertoli-spermatid (apical ES) interface and at the Sertoli cell-cell (basal ES) interface. These data are carefully evaluated in light of other recent findings herein regarding the role of drebrin in actin filament organization at the ES. We also provide the hypothetical model regarding its involvement in germ cell transport during the epithelial cycle in the seminiferous epithelium to support spermatogenesis.
Collapse
Affiliation(s)
- Haiqi Chen
- The Mary M. Wohlford Laboratory for Male Contraceptive Research, Center for Biomedical Research, Population Council, 1230 York Ave., New York, NY, 10065, USA
| | - Michelle W M Li
- The Mary M. Wohlford Laboratory for Male Contraceptive Research, Center for Biomedical Research, Population Council, 1230 York Ave., New York, NY, 10065, USA
| | - C Yan Cheng
- The Mary M. Wohlford Laboratory for Male Contraceptive Research, Center for Biomedical Research, Population Council, 1230 York Ave., New York, NY, 10065, USA.
| |
Collapse
|
14
|
Cofilin-1 and Other ADF/Cofilin Superfamily Members in Human Malignant Cells. Int J Mol Sci 2016; 18:ijms18010010. [PMID: 28025492 PMCID: PMC5297645 DOI: 10.3390/ijms18010010] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Revised: 11/18/2016] [Accepted: 12/01/2016] [Indexed: 12/12/2022] Open
Abstract
Identification of actin-depolymerizing factor homology (ADF-H) domains in the structures of several related proteins led first to the formation of the ADF/cofilin family, which then expanded to the ADF/cofilin superfamily. This superfamily includes the well-studied cofilin-1 (Cfl-1) and about a dozen different human proteins that interact directly or indirectly with the actin cytoskeleton, provide its remodeling, and alter cell motility. According to some data, Cfl-1 is contained in various human malignant cells (HMCs) and is involved in the formation of malignant properties, including invasiveness, metastatic potential, and resistance to chemotherapeutic drugs. The presence of other ADF/cofilin superfamily proteins in HMCs and their involvement in the regulation of cell motility were discovered with the use of various OMICS technologies. In our review, we discuss the results of the study of Cfl-1 and other ADF/cofilin superfamily proteins, which may be of interest for solving different problems of molecular oncology, as well as for the prospects of further investigations of these proteins in HMCs.
Collapse
|
15
|
Iyama S, Ono M, Kawai-Nakahara H, Husni RE, Dai T, Shiozawa T, Sakata A, Kohrogi H, Noguchi M. Drebrin: A new oncofetal biomarker associated with prognosis of lung adenocarcinoma. Lung Cancer 2016; 102:74-81. [PMID: 27987592 DOI: 10.1016/j.lungcan.2016.10.013] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2016] [Accepted: 10/26/2016] [Indexed: 11/26/2022]
Abstract
OBJECTIVES With the aim of searching for novel oncofetal tumor biomarkers of lung adenocarcinoma other than carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP), we developed a strategy involving monoclonal antibodies generated from embryonic tissue of miniature swine. MATERIALS AND METHODS Using immunohistochemistry, we selected suitable hybridoma clones that were reactive against swine fetal lung but not adult lung using tissue microarray loading of human normal lung, lung cancer, and fetal and adult swine tissues. RESULTS The selected clones included several that were uniquely reactive against both swine fetal lung and human lung adenocarcinoma, and protein microarray revealed that the antigen they recognized was "drebrin" (DBN1). We then examined the association between the pattern of drebrin expression and the clinicopathological characteristics of lung adenocarcinoma using surgically resected samples of human lung adenocarcinoma. Two hundred formalin-fixed and paraffin-embedded tumor samples were immunostained for drebrin using clone B246, one of the clones that were reactive against drebrin. The cases were divided into those with strong (n=85) and weak (n=115) drebrin expression. In terms of disease-free survival, cases showing strong drebrin expression had a significantly poorer prognosis than those with weak drebrin expression (p=0.033). CONCLUSION The present findings indicate that "drebrin" is a unique oncofetal protein that can be applied as a new biomarker of lung adenocarcinoma.
Collapse
Affiliation(s)
- Shinji Iyama
- Doctoral Program in Biomedical Science, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan; Department of Respiratory Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
| | - Masao Ono
- Department of Pathology, National Hospital Organization Mito Medical Center, Ibaraki, Japan
| | - Hitomi Kawai-Nakahara
- Doctoral Program in Biomedical Science, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan; Department of Pathology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
| | - Ryan Edbert Husni
- Doctoral Program in Biomedical Science, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan
| | - Tomoko Dai
- Doctoral Program in Biomedical Science, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan
| | - Toshihiro Shiozawa
- Department of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
| | - Akiko Sakata
- Department of Pathology, Hitachi General Hospital, Ibaraki, Japan
| | - Hirotsugu Kohrogi
- Department of Respiratory Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
| | - Masayuki Noguchi
- Department of Pathology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
| |
Collapse
|
16
|
Pan W, Han S, Kang L, Li S, Du J, Cui H. Effects of dihydrotestosterone on synaptic plasticity of the hippocampus in mild cognitive impairment male SAMP8 mice. Exp Ther Med 2016; 12:1455-1463. [PMID: 27588067 PMCID: PMC4997989 DOI: 10.3892/etm.2016.3470] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2016] [Accepted: 06/21/2016] [Indexed: 01/03/2023] Open
Abstract
The current study focused on how dihydrotestosterone (DHT) regulates synaptic plasticity in the hippocampus of mild cognitive impairment male senescence-accelerated mouse prone 8 (SAMP8) mice. Five-month-old SAMP8 mice were divided into the control, castrated and castrated-DHT groups, in which the mice were castrated and treated with physiological doses of DHT for a period of 2 months. To determine the regulatory mechanisms of DHT in the cognitive capacity, the effects of DHT on the morphology of the synapse and the expression of synaptic marker proteins in the hippocampus were investigated using immunohistochemistry, qPCR and western blot analysis. The results showed that the expression of cAMP-response element binding protein (CREB), postsynaptic density protein 95 (PSD95), synaptophysin (SYN) and developmentally regulated brain protein (Drebrin) was reduced in the castrated group compared to the control group. However, DHT promoted the expression of CREB, PSD95, SYN and Drebrin in the hippocampus of the castrated-DHT group. Thus, androgen depletion impaired the synaptic plasticity in the hippocampus of SAMP8 and accelerated the development of Alzheimer's disease (AD)-like neuropathology, suggesting that a similar mechanism may underlie the increased risk for AD in men with low testosterone. In addition, DHT regulated synaptic plasticity in the hippocampus of mild cognitive impairment (MCI) SAMP8 mice and delayed the progression of disease to Alzheimer's dementia. In conclusion, androgen-based hormone therapy is a potentially useful strategy for preventing the progression of MCI in aging men. Androgens enhance synaptic markers (SYN, PSD95, and Drebrin), activate CREB, modulate the fundamental biology of synaptic structure, and lead to the structural changes of plasticity in the hippocampus, all of which result in improved cognitive function.
Collapse
Affiliation(s)
- Wensen Pan
- Department of Human Anatomy, Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China; Department of Respiration Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, P.R. China
| | - Shuo Han
- Department of Human Anatomy, Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China
| | - Lin Kang
- Department of Human Anatomy, Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China
| | - Sha Li
- Department of Human Anatomy, Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China
| | - Juan Du
- Department of Human Anatomy, Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China
| | - Huixian Cui
- Department of Human Anatomy, Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China; Hebei Key Laboratory for Brain Aging and Cognitive Neuroscience, Shijiazhuang, Hebei 050031, P.R. China
| |
Collapse
|
17
|
Xu SQ, Buraschi S, Morcavallo A, Genua M, Shirao T, Peiper SC, Gomella LG, Birbe R, Belfiore A, Iozzo RV, Morrione A. A novel role for drebrin in regulating progranulin bioactivity in bladder cancer. Oncotarget 2016; 6:10825-39. [PMID: 25839164 PMCID: PMC4484422 DOI: 10.18632/oncotarget.3424] [Citation(s) in RCA: 43] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2014] [Accepted: 02/23/2015] [Indexed: 01/13/2023] Open
Abstract
We recently established a critical role for the growth factor progranulin in bladder cancer insofar as progranulin promotes urothelial cancer cell motility and contributes, as an autocrine growth factor, to the transformed phenotype by modulating invasion and anchorage-independent growth. In addition, progranulin expression is upregulated in invasive bladder cancer tissues compared to normal controls. However, the molecular mechanisms of progranulin action in bladder cancer have not been fully elucidated. In this study, we searched for novel progranulin-interacting proteins using pull-down assays with recombinant progranulin and proteomics. We discovered that drebrin, an F-actin binding protein, bound progranulin in urothelial cancer cells. We characterized drebrin function in urothelial cancer cell lines and showed that drebrin is critical for progranulin-dependent activation of the Akt and MAPK pathways and modulates motility, invasion and anchorage-independent growth. In addition, drebrin regulates tumor formation in vivo and its expression is upregulated in bladder cancer tissues compared to normal tissue controls. Our data are translationally relevant as indicate that drebrin exerts an essential functional role in the regulation of progranulin action and may constitute a novel target for therapeutic intervention in bladder tumors. In addition, drebrin may serve as novel biomarker for bladder cancer.
Collapse
Affiliation(s)
- Shi-Qiong Xu
- Department of Urology and Biology of Prostate Cancer Program, Thomas Jefferson University, Philadelphia, PA, USA
| | - Simone Buraschi
- Department of Pathology, Anatomy and Cell Biology and Cancer Cell Biology and Signaling Program, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
| | - Alaide Morcavallo
- Department of Urology and Biology of Prostate Cancer Program, Thomas Jefferson University, Philadelphia, PA, USA.,Department of Health and Endocrinology, University Magna Graecia of Catanzaro, Catanzaro, Italy
| | - Marco Genua
- Department of Urology and Biology of Prostate Cancer Program, Thomas Jefferson University, Philadelphia, PA, USA
| | - Tomoaki Shirao
- Department of Neurobiology and Behavior, Gunma University School of Medicine, Showamachi, Maebashi, Japan
| | - Stephen C Peiper
- Department of Pathology, Anatomy and Cell Biology and Cancer Cell Biology and Signaling Program, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
| | - Leonard G Gomella
- Department of Urology and Biology of Prostate Cancer Program, Thomas Jefferson University, Philadelphia, PA, USA
| | - Ruth Birbe
- Department of Pathology, Anatomy and Cell Biology and Cancer Cell Biology and Signaling Program, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
| | - Antonino Belfiore
- Department of Health and Endocrinology, University Magna Graecia of Catanzaro, Catanzaro, Italy
| | - Renato V Iozzo
- Department of Pathology, Anatomy and Cell Biology and Cancer Cell Biology and Signaling Program, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
| | - Andrea Morrione
- Department of Urology and Biology of Prostate Cancer Program, Thomas Jefferson University, Philadelphia, PA, USA
| |
Collapse
|
18
|
Ma L, Li Y, Wang R. Drebrin and cognitive impairment. Clin Chim Acta 2015; 451:121-4. [DOI: 10.1016/j.cca.2015.06.021] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2015] [Revised: 06/14/2015] [Accepted: 06/19/2015] [Indexed: 10/23/2022]
|
19
|
Chinello C, Cazzaniga M, De Sio G, Smith AJ, Grasso A, Rocco B, Signorini S, Grasso M, Bosari S, Zoppis I, Mauri G, Magni F. Tumor size, stage and grade alterations of urinary peptidome in RCC. J Transl Med 2015; 13:332. [PMID: 26482227 PMCID: PMC4617827 DOI: 10.1186/s12967-015-0693-8] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2015] [Accepted: 10/10/2015] [Indexed: 01/23/2023] Open
Abstract
Background Several promising biomarkers have been found for RCC, but none of them has been used in clinical practice for predicting tumour progression. The most widely used features for predicting tumour aggressiveness still remain the cancer stage, size and grade. Therefore, the aim of our study is to investigate the urinary peptidome to search and identify peptides whose concentrations in urine are linked to tumour growth measure and clinical data. Methods A proteomic approach applied to ccRCC urinary peptidome (n = 117) based on prefractionation with activated magnetic beads followed by MALDI-TOF profiling was used. A systematic correlation study was performed on urinary peptide profiles obtained from MS analysis. Peptide identity was obtained by LC–ESI–MS/MS. Results Fifteen, twenty-six and five peptides showed a statistically significant alteration of their urinary concentration according to tumour size, pT and grade, respectively. Furthermore, 15 and 9 signals were observed to have urinary levels statistically modified in patients at different pT or grade values, even at very early stages. Among them, C1RL, A1AGx, ZAG2G, PGBM, MMP23, GP162, ADA19, G3P, RSPH3, DREB, NOTC2 SAFB2 and CC168 were identified. Conclusions We identified several peptides whose urinary abundance varied according to tumour size, stage and grade. Among them, several play a possible role in tumorigenesis, progression and aggressiveness. These results could be a useful starting point for future studies aimed at verifying their possible use in the managements of RCC patients. Electronic supplementary material The online version of this article (doi:10.1186/s12967-015-0693-8) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Clizia Chinello
- Department of Health Science, School of Medicine, University of Milano-Bicocca (UNIMIB), Via Cadore, 48, 20900, Monza, Italy.
| | - Marta Cazzaniga
- Department of Health Science, School of Medicine, University of Milano-Bicocca (UNIMIB), Via Cadore, 48, 20900, Monza, Italy.
| | - Gabriele De Sio
- Department of Health Science, School of Medicine, University of Milano-Bicocca (UNIMIB), Via Cadore, 48, 20900, Monza, Italy.
| | - Andrew James Smith
- Department of Health Science, School of Medicine, University of Milano-Bicocca (UNIMIB), Via Cadore, 48, 20900, Monza, Italy.
| | - Angelica Grasso
- Urology Unit, Department of Specialistic Surgical Sciences, Ospedale Maggiore Policlinico Foundation, Milan, Italy.
| | - Bernardo Rocco
- Urology Unit, Department of Specialistic Surgical Sciences, Ospedale Maggiore Policlinico Foundation, Milan, Italy.
| | | | - Marco Grasso
- Department of Surgical Pathology, Cytology, Medical Genetics and Nephropathology, Azienda Ospedaliera San Gerardo, Monza, Italy.
| | - Silvano Bosari
- Department of Medicine, Surgery and Dental Sciences, Pathology Unit, IRCCS-Policlinico Foundation, Mangiagalli and Regina Elena, University of Milan, Milan, Italy.
| | - Italo Zoppis
- Department of Informatics, Systems and Communication, University of Milano-Bicocca, Milan, Italy.
| | - Giancarlo Mauri
- Department of Informatics, Systems and Communication, University of Milano-Bicocca, Milan, Italy.
| | - Fulvio Magni
- Department of Health Science, School of Medicine, University of Milano-Bicocca (UNIMIB), Via Cadore, 48, 20900, Monza, Italy.
| |
Collapse
|
20
|
Di Luca A, Henry M, Meleady P, O'Connor R. Label-free LC-MS analysis of HER2+ breast cancer cell line response to HER2 inhibitor treatment. ACTA ACUST UNITED AC 2015; 23:40. [PMID: 26238995 PMCID: PMC4524286 DOI: 10.1186/s40199-015-0120-y] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2015] [Accepted: 06/24/2015] [Indexed: 12/21/2022]
Abstract
BACKGROUND Human epidermal growth-factor receptor (HER)-2 is overexpressed in 25 % of breast-cancers and is associated with an aggressive form of the disease with significantly shortened disease free and overall survival. In recent years, the use of HER2-targeted therapies, monoclonal-antibodies and small molecule tyrosine-kinase inhibitors has significantly improved the clinical outcome for HER2-positive breast-cancer patients. However, only a fraction of HER2-amplified patients will respond to therapy and the use of these treatments is often limited by tumour drug insensitivity or resistance and drug toxicities. Currently there is no way to identify likely responders or rational combinations with the potential to improve HER2-focussed treatment outcome. METHODS In order to further understand the molecular mechanisms of treatment-response with HER2-inhibitors, we used a highly-optimised and reproducible quantitative label-free LC-MS strategy to characterize the proteomes of HER2-overexpressing breast-cancer cell-lines (SKBR3, BT474 and HCC1954) in response to drug-treatment with HER2-inhibitors (lapatinib, neratinib or afatinib). RESULTS Following 12 ours treatment with different HER2-inhibitors in the BT474 cell-line; compared to the untreated cells, 16 proteins changed significantly in abundance following lapatinib treatment (1 μM), 21 proteins changed significantly following neratinib treatment (150 nM) and 38 proteins changed significantly following afatinib treatment (150 nM). Whereas following 24 hours treatment with neratinib (200 nM) 46 proteins changed significantly in abundance in the HCC1954 cell-line and 23 proteins in the SKBR3 cell-line compared to the untreated cells. Analysing the data we found that, proteins like trifunctional-enzyme subunit-alpha, mitochondrial; heterogeneous nuclear ribonucleoprotein-R and lamina-associated polypeptide 2, isoform alpha were up-regulated whereas heat shock cognate 71 kDa protein was down-regulated in 3 or more comparisons. CONCLUSION This proteomic study highlights several proteins that are closely associated with early HER2-inhibitor response and will provide a valuable resource for further investigation of ways to improve efficacy of breast-cancer treatment.
Collapse
Affiliation(s)
- Alessio Di Luca
- National Institute for Cellular Biotechnology, DCU, Glasnevin, Dublin 9, Dublin, Ireland.
| | - Michael Henry
- National Institute for Cellular Biotechnology, DCU, Glasnevin, Dublin 9, Dublin, Ireland.
| | - Paula Meleady
- National Institute for Cellular Biotechnology, DCU, Glasnevin, Dublin 9, Dublin, Ireland.
| | - Robert O'Connor
- National Institute for Cellular Biotechnology, DCU, Glasnevin, Dublin 9, Dublin, Ireland. .,School of Nursing and Human Sciences, DCU, Glasnevin, Dublin 9, Dublin, Ireland.
| |
Collapse
|
21
|
Sonego M, Oberoi M, Stoddart J, Gajendra S, Hendricusdottir R, Oozeer F, Worth DC, Hobbs C, Eickholt BJ, Gordon-Weeks PR, Doherty P, Lalli G. Drebrin regulates neuroblast migration in the postnatal mammalian brain. PLoS One 2015; 10:e0126478. [PMID: 25945928 PMCID: PMC4422745 DOI: 10.1371/journal.pone.0126478] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2014] [Accepted: 04/02/2015] [Indexed: 01/13/2023] Open
Abstract
After birth, stem cells in the subventricular zone (SVZ) generate neuroblasts that migrate along the rostral migratory stream (RMS) to become interneurons in the olfactory bulb (OB). This migration is crucial for the proper integration of newborn neurons in a pre-existing synaptic network and is believed to play a key role in infant human brain development. Many regulators of neuroblast migration have been identified; however, still very little is known about the intracellular molecular mechanisms controlling this process. Here, we have investigated the function of drebrin, an actin-binding protein highly expressed in the RMS of the postnatal mammalian brain. Neuroblast migration was monitored both in culture and in brain slices obtained from electroporated mice by time-lapse spinning disk confocal microscopy. Depletion of drebrin using distinct RNAi approaches in early postnatal mice affects neuroblast morphology and impairs neuroblast migration and orientation in vitro and in vivo. Overexpression of drebrin also impairs migration along the RMS and affects the distribution of neuroblasts at their final destination, the OB. Drebrin phosphorylation on Ser142 by Cyclin-dependent kinase 5 (Cdk5) has been recently shown to regulate F-actin-microtubule coupling in neuronal growth cones. We also investigated the functional significance of this phosphorylation in RMS neuroblasts using in vivo postnatal electroporation of phosphomimetic (S142D) or non-phosphorylatable (S142A) drebrin in the SVZ of mouse pups. Preventing or mimicking phosphorylation of S142 in vivo caused similar effects on neuroblast dynamics, leading to aberrant neuroblast branching. We conclude that drebrin is necessary for efficient migration of SVZ-derived neuroblasts and propose that regulated phosphorylation of drebrin on S142 maintains leading process stability for polarized migration along the RMS, thus ensuring proper neurogenesis.
Collapse
Affiliation(s)
- Martina Sonego
- Wolfson Centre for Age-Related Diseases, King’s College London, London, United Kingdom
| | - Michelle Oberoi
- Department of Anatomy and Neurobiology, University of California Irvine, Irvine, California, United States of America
| | - Jake Stoddart
- Wolfson Centre for Age-Related Diseases, King’s College London, London, United Kingdom
| | - Sangeetha Gajendra
- MRC Centre for Developmental Neurobiology, King’s College London, London, United Kingdom
| | - Rita Hendricusdottir
- MRC Centre for Developmental Neurobiology, King’s College London, London, United Kingdom
| | - Fazal Oozeer
- MRC Centre for Developmental Neurobiology, King’s College London, London, United Kingdom
| | - Daniel C. Worth
- MRC Centre for Developmental Neurobiology, King’s College London, London, United Kingdom
| | - Carl Hobbs
- Wolfson Centre for Age-Related Diseases, King’s College London, London, United Kingdom
| | - Britta J. Eickholt
- Cluster of Excellence NeuroCure and Institute of Biochemistry, Charité —Universitätsmedizin Berlin, Berlin, Germany
| | | | - Patrick Doherty
- Wolfson Centre for Age-Related Diseases, King’s College London, London, United Kingdom
| | - Giovanna Lalli
- Wolfson Centre for Age-Related Diseases, King’s College London, London, United Kingdom
- * E-mail:
| |
Collapse
|
22
|
Wong SY, Kumar S. Matrix regulation of tumor-initiating cells. PROGRESS IN MOLECULAR BIOLOGY AND TRANSLATIONAL SCIENCE 2014; 126:243-56. [PMID: 25081621 DOI: 10.1016/b978-0-12-394624-9.00010-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The recognition that the progression of many tumors may be driven by specific subpopulations of cells with stem/progenitor-like properties (tumor-initiating cells or TICs, a.k.a. cancer stem cells) represents an important recent paradigm shift in cancer biology and therapeutics. TICs in solid tissues are expected to interface with the extracellular matrix (ECM), which can strongly influence cell behavior through a variety of biochemical and biophysical mechanisms. Understanding ECM regulation of TIC behavior is important for developing strategies to isolate, expand, and characterize TICs in a laboratory setting and for understanding the roles ECM-based inputs may play in disease progression and therapy. In this chapter, we discuss how the ECM regulates TICs, starting with a brief overview of TIC biology, isolation, and characterization, molecular mechanisms through which TICs may be regulated by ECM-based signals, and the potential importance of these signals to TIC-driven tumor progression and metastasis.
Collapse
Affiliation(s)
- Sophie Y Wong
- Department of Bioengineering, University of California, Berkeley, Berkeley, California, USA
| | - Sanjay Kumar
- Department of Bioengineering, University of California, Berkeley, Berkeley, California, USA
| |
Collapse
|
23
|
Sayegh ET, Kaur G, Bloch O, Parsa AT. Systematic review of protein biomarkers of invasive behavior in glioblastoma. Mol Neurobiol 2013; 49:1212-44. [PMID: 24271659 DOI: 10.1007/s12035-013-8593-5] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2013] [Accepted: 11/11/2013] [Indexed: 12/26/2022]
Abstract
Glioblastoma (GBM) is an aggressive and incurable brain tumor with a grave prognosis. Recurrence is inevitable even with maximal surgical resection, in large part because GBM is a highly invasive tumor. Invasiveness also contributes to the failure of multiple cornerstones of GBM therapy, including radiotherapy, temozolomide chemotherapy, and vascular endothelial growth factor blockade. In recent years there has been significant progress in the identification of protein biomarkers of invasive phenotype in GBM. In this article, we comprehensively review the literature and survey a broad spectrum of biomarkers, including proteolytic enzymes, extracellular matrix proteins, cell adhesion molecules, neurodevelopmental factors, cell signaling and transcription factors, angiogenic effectors, metabolic proteins, membrane channels, and cytokines and chemokines. In light of the marked variation seen in outcomes in GBM patients, the systematic use of these biomarkers could be used to form a framework for better prediction, prognostication, and treatment selection, as well as the identification of molecular targets for further laboratory investigation and development of nascent, directed therapies.
Collapse
Affiliation(s)
- Eli T Sayegh
- Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, 676 N. St. Clair Street, Suite 2210, Chicago, IL, 60611-2911, USA
| | | | | | | |
Collapse
|